PDDC is the first potent, selective, orally-available, and brain-penetrable nSMase2 (neutral sphingomyelinase 2) inhibitor with pIC50 of 6.57.
PDDC inhibited release of ADEVs in tissue culture and in vivo, capable of dose-dependently reducing EVs release in vitro and in vivo.
PDDC reduced these IL-1β-induced changes implicating nSMase2 inhibition as a therapeutic target for acute brain injury.
